The report by India Ratings and Research (Ind-Ra) said the growth in the sector will be at 7.5-8.0 per cent year on year for FY25. Cardiac therapies outperformed growth with 10.8 per cent growth in MAT and a 13.7 per cent increase in monthly market share. The Indian pharma sector has grown at 8 per cent CAGR and has also seen a 9% increase in export rates in 2024, according to a report by McKinsey & Company. The country also emerged as the world’s largest supplier of generic medicines, with a 9 per cent pharma export growth rate, nearly double the global average, the report said. The sector reported growth at an average of 7.3% year-to-date (YTD) in FY25, led by price growth (5.5% YoY) and new launches growth (2.7%YoY) The moving annual total (MAT) — or the 12-month rolling sales of overall pharma products — saw an 8.1 per cent surge in February.